Last reviewed · How we verify
MAX-40279
At a glance
| Generic name | MAX-40279 |
|---|---|
| Also known as | MAX-40279-01 capsule, MAX-40279-001 |
| Sponsor | Maxinovel Pty., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors (PHASE1, PHASE2)
- A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors (PHASE1)
- MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) (PHASE1)
- MAX-40279-01 in Patients With Advanced Solid Tumors (PHASE1)
- Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) (PHASE1)
- A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer (PHASE2)
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAX-40279 CI brief — competitive landscape report
- MAX-40279 updates RSS · CI watch RSS
- Maxinovel Pty., Ltd. portfolio CI